Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Tidal Investments LLC

Tidal Investments LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 257.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,654 shares of the company’s stock after buying an additional 2,633 shares during the period. Tidal Investments LLC’s holdings in Medpace were worth $1,220,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in Medpace in the third quarter valued at $175,000. Sanctuary Advisors LLC grew its holdings in shares of Medpace by 21.2% during the third quarter. Sanctuary Advisors LLC now owns 4,120 shares of the company’s stock worth $1,392,000 after buying an additional 721 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $1,503,000. Sunbelt Securities Inc. raised its position in Medpace by 34.9% during the 3rd quarter. Sunbelt Securities Inc. now owns 727 shares of the company’s stock worth $243,000 after buying an additional 188 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in shares of Medpace by 33.0% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,758 shares of the company’s stock worth $599,000 after acquiring an additional 436 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MEDP shares. Truist Financial dropped their price target on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $420.00 to $350.00 in a report on Friday, September 27th. Finally, Redburn Atlantic initiated coverage on shares of Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $380.56.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $331.00 on Thursday. The firm’s 50-day moving average is $339.54 and its two-hundred day moving average is $366.89. Medpace Holdings, Inc. has a 12-month low of $277.72 and a 12-month high of $459.77. The company has a market capitalization of $10.29 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the prior year, the firm earned $2.22 EPS. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. On average, analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.